Clinical trial
A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and…
NCT00320541 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00320541 |
|---|---|
| Title | A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer |
| Official title | A Randomized Phase II Trial of Paclitaxel and Bevacizumab Versus Gemcitabine, Paclitaxel, and Bevacizumab as First Line Treatment for Locally Advanced or Metastatic Breast Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | gemcitabine, paclitaxel, bevacizumab |
| Enrollment | 187 |
| Start date | May 1, 2006 |
| Primary completion | Apr 1, 2009 |
| Completion | Aug 1, 2012 |
| First posted | May 3, 2006 |
| Last update posted | Jul 22, 2013 |
| Countries | Puerto Rico, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: